Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Pulmonology · Pulmonary Mycobacterium avium complex infection

Should I Get Immune or Lung Testing for Pulmonary MAC?

At a Glance

Pulmonary MAC alone does not mean severe immune deficiency. Doctors review CT scans, medications, and medical history and may order basic immune blood tests. Further testing depends on recurrent infections or clues to bronchiectasis, genetic disease, or autoimmune conditions.

Being diagnosed with pulmonary Mycobacterium avium complex (MAC) often leads to a pressing question: Why did I get this? Is my immune system failing?

The short answer is no. A pulmonary MAC diagnosis alone does not mean you have a severe, body-wide immune deficiency [1]. In fact, many people who develop MAC in their lungs have no single, obvious immune or genetic defect that explains their infection [1].

What This Diagnosis Does and Does Not Mean

  • It is not your fault: Developing MAC does not mean you did something wrong, “caused” your illness, or that your immune system is failing.
  • Low body weight is a risk marker: MAC is frequently seen in people with low body weight who have a nodular/bronchiectatic pattern (a specific pattern of airway damage seen on imaging) [1]. However, this is an association, not proof that poor nutrition caused the infection.
  • It is usually environmental: MAC bacteria are everywhere in water and soil. They usually only establish an infection when there is an issue with the lungs’ local defenses or airway clearance, though many patients never have one identifiable explanation.

While there may be no single cause, your doctor will likely evaluate you for certain underlying conditions to ensure nothing is missed.

Structural Lung Diseases

The most common factors that increase the risk for pulmonary MAC are structural changes in the lungs. When the airways are damaged, they struggle to clear out mucus and inhaled bacteria normally [2].

  • Bronchiectasis: This condition is defined radiologically by permanent widening of the airways, often accompanied by mucus plugging [3][4]. The relationship between MAC and bronchiectasis is bidirectional: underlying bronchiectasis predisposes you to MAC, but the chronic inflammation from a MAC infection can also cause or worsen airway damage. Clinicians use prior CT scans to help judge what came first.
  • COPD and Emphysema: Chronic obstructive pulmonary disease and a history of lung damage from prior infections (like tuberculosis) can also make it easier for MAC to take hold [5].

Basic Immune System Testing

While severe immunodeficiencies are usually not the culprit, major respiratory societies (such as the European Respiratory Society) recommend some baseline blood tests if you have bronchiectasis [6].

  • Immunoglobulins: These are antibodies your immune system makes to fight infections. Your doctor will likely check basic quantitative immunoglobulins (IgG, IgA, and IgM) to make sure your body is producing enough antibodies [6][3].
  • Complete Blood Count (CBC): A standard CBC helps your doctor check for chronically low white blood cell counts [3].

Note: Normal immunoglobulin and CBC results do not test for every possible immune problem. However, expanded testing (like vaccine-specific antibody responses or specialized lymphocyte testing) is usually only ordered if you have a history of recurrent, unusual, or severe childhood infections.

  • HIV Testing: HIV testing is commonly considered or recommended in the initial evaluation [7]. It is important to know that ordering this test is a routine guideline precaution and does not mean your clinician suspects you have HIV. While disseminated (body-wide) MAC is strongly associated with advanced HIV, isolated pulmonary MAC can occur in anyone regardless of their HIV status [8].

Connective-Tissue Diseases and Medications

Your doctor will review your medical history, as some treatments and conditions can alter your immune defenses.

  • Connective-Tissue Diseases: Conditions like rheumatoid arthritis and Sjögren’s syndrome can affect lung tissue and alter your immune defenses [9][10]. However, indiscriminate autoimmune blood testing can produce confusing false-positive results. Evaluation is usually guided by specific symptoms like inflammatory joint pain, dry eyes or mouth, or Raynaud’s phenomenon (fingers turning white or blue in the cold).
  • Medications: Drugs used to treat cancer, prevent organ transplant rejection, or manage autoimmune diseases (like systemic steroids, rituximab, or biologics) can increase your risk for MAC [2][11]. Inhaled corticosteroids used for asthma or COPD can also be a risk factor, depending on the dose [12]. Do not stop inhalers, steroids, biologics, or other prescribed medicines without consulting your prescribing clinician, as the risks and benefits must be balanced carefully.

Individualized Specialized Testing

There is no fixed stopping point for a lung disease evaluation; further testing depends on your personal and family history.

  • Cystic Fibrosis (CF): Doctors may evaluate you for CF if you have a history of chronic cough, male infertility, pancreatic issues, or a family history of CF [13]. Evaluation usually includes a sweat chloride test and genetic testing for mutations in the CFTR gene [14][15]. Having a CFTR genetic variant alone does not establish a cystic fibrosis diagnosis; it must be interpreted alongside other tests.
  • Primary Ciliary Dyskinesia (PCD): This is a genetic disorder where the microscopic hairs (cilia) in the lungs fail to sweep away mucus properly. Testing is usually reserved for people with lifelong wet coughs, recurrent ear and sinus infections since childhood, or organs that are reversed in the body [13].
  • Other Causes of Bronchiectasis: Your doctor might also evaluate you for Allergic Bronchopulmonary Aspergillosis (ABPA) (an allergic reaction to fungus), Alpha-1 antitrypsin deficiency (a genetic condition affecting the lungs and liver), or chronic acid reflux (which can cause micro-aspiration into the lungs) [6][3].

What Happens After the Work-Up?

Finding no underlying cause is very common and does not invalidate your MAC diagnosis. If a specific cause is found, it will help tailor your care. For example, a diagnosis of true bronchiectasis will lead to a focus on airway clearance techniques. If an immune or medication-related issue is identified, it may prompt a referral to a specialist to adjust your overall treatment plan and keep your lungs as healthy as possible.

Common questions in this guide

Does pulmonary MAC mean that I have a serious immune deficiency?
No. Pulmonary MAC by itself does not show that your whole-body immune system is failing, and many people have no single identifiable immune or genetic problem. Clinicians may still perform a focused evaluation to look for treatable contributors.
What basic tests are usually considered after a pulmonary MAC diagnosis?
Depending on your findings, the initial work-up may include quantitative immunoglobulins, which measure IgG, IgA, and IgM antibodies, along with a complete blood count. HIV testing is also commonly considered. Normal results do not rule out every immune problem, so additional tests are based on your history.
Could bronchiectasis or another lung condition explain my pulmonary MAC?
Yes. Bronchiectasis, COPD, emphysema, and damage from previous infections can make it harder for the airways to clear mucus and bacteria. CT scans and comparison with older images can help determine whether bronchiectasis came before MAC or developed with it.
Can my medicines increase my risk of pulmonary MAC?
Yes. Systemic steroids, rituximab, biologic medicines, cancer or transplant treatments, and some inhaled corticosteroids can weaken immune defenses or otherwise increase risk. Do not stop an inhaler, steroid, biologic, or other prescription on your own; ask the prescribing clinician to review the benefits and risks.
When would testing for cystic fibrosis or a cilia disorder be useful?
Testing is individualized and may be considered with lifelong wet cough, repeated ear or sinus infections beginning in childhood, male infertility, pancreatic problems, a family history of cystic fibrosis, or organs positioned in reverse. Evaluation for cystic fibrosis may include a sweat chloride test and CFTR genetic testing, while primary ciliary dyskinesia requires different specialized testing.
What if my immune and lung tests do not find an underlying cause?
That is common and does not invalidate a pulmonary MAC diagnosis. Your clinicians can still plan care based on your lung findings, while any identified cause may guide airway-clearance measures, medication review, or specialist referral.
When should I be evaluated for an autoimmune condition?
Further autoimmune evaluation is usually guided by symptoms such as inflammatory joint pain, dry eyes or mouth, Raynaud's phenomenon, or skin changes. Broad testing without a clinical reason can produce confusing false-positive results, so discuss specific symptoms with your clinician.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my CT scan, do I have underlying structural lung changes like true bronchiectasis, or just mucus plugging?
  2. 2.Given my symptom history, should we check my basic immunoglobulin levels and do standard bloodwork, or do you feel my immune system is functioning normally?
  3. 3.Are any of my current medications, including inhalers or treatments for other conditions, increasing my risk for MAC? Should any be adjusted, and who coordinates that?
  4. 4.Do I have any clinical features that suggest I should be tested for a genetic airway clearance disorder like cystic fibrosis or primary ciliary dyskinesia?
  5. 5.Is there anything in my medical history, such as joint pain, dry eyes, or skin changes, that warrants further autoimmune evaluation?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Pathophysiology of pulmonary nontuberculous mycobacterial (NTM) disease.

    Matsuyama M, Matsumura S, Nonaka M, et al.

    Respiratory investigation 2023; (61(2)):135-148 doi:10.1016/j.resinv.2022.12.002.

    PMID: 36640546
  2. 2

    Epidemiology of Nontuberculous Mycobacteriosis.

    Adjemian J, Daniel-Wayman S, Ricotta E, Prevots DR

    Seminars in respiratory and critical care medicine 2018; (39(3)):325-335 doi:10.1055/s-0038-1651491.

    PMID: 30071547
  3. 3

    Non-Cystic Fibrosis Bronchiectasis in Adults: A Review.

    Barker AF, Karamooz E

    JAMA 2025; (334(3)):253-264 doi:10.1001/jama.2025.2680.

    PMID: 40293759
  4. 4

    Clinical characteristics of patients with bronchiectasis with nontuberculous mycobacterial disease in Mainland China: a single center cross-sectional study.

    Yin H, Gu X, Wang Y, et al.

    BMC infectious diseases 2021; (21(1)):1216 doi:10.1186/s12879-021-06917-8.

    PMID: 34872515
  5. 5

    Nontuberculous Mycobacteria in Cystic Fibrosis.

    Furukawa BS, Flume PA

    Seminars in respiratory and critical care medicine 2018; (39(3)):383-391 doi:10.1055/s-0038-1651495.

    PMID: 30071553
  6. 6

    Bronchiectasis: a case-based approach to investigation and management.

    Contarini M, Finch S, Chalmers JD

    European respiratory review : an official journal of the European Respiratory Society 2018; (27(149)) doi:10.1183/16000617.0016-2018.

    PMID: 29997246
  7. 7

    Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

    Daley CL, Iaccarino JM, Lange C, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020; (71(4)):e1-e36 doi:10.1093/cid/ciaa241.

    PMID: 32628747
  8. 8

    Mycobacterium avium Complex Disease.

    Daley CL

    Microbiology spectrum 2017; (5(2)) doi:10.1128/microbiolspec.TNMI7-0045-2017.

    PMID: 28429679
  9. 9

    Growing from common ground: nontuberculous mycobacteria and bronchiectasis.

    Van Braeckel E, Bosteels C

    European respiratory review : an official journal of the European Respiratory Society 2024; (33(173)) doi:10.1183/16000617.0058-2024.

    PMID: 38960614
  10. 10

    Increasing patients with pulmonary Mycobacterium avium complex disease and associated underlying diseases in Japan.

    Ito Y, Hirai T, Fujita K, et al.

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2015; (21(5)):352-6.

    PMID: 25640532
  11. 11

    Characteristics of Nontuberculous Mycobacterial Infections at a Midwestern Tertiary Hospital: A Retrospective Study of 365 Patients.

    Hannah CE, Ford BA, Chung J, et al.

    Open forum infectious diseases 2020; (7(6)):ofaa173 doi:10.1093/ofid/ofaa173.

    PMID: 32587875
  12. 12

    Development of allergic bronchopulmonary aspergillosis in a patient with nontuberculous mycobacterial-pulmonary disease successfully treated with dupilumab: A case report and literature review.

    Onozato R, Miyata J, Asakura T, et al.

    Respirology case reports 2024; (12(7)):e01432 doi:10.1002/rcr2.1432.

    PMID: 38988827
  13. 13

    Nontuberculous Mycobacteria, Mucociliary Clearance, and Bronchiectasis.

    Retuerto-Guerrero M, López-Medrano R, de Freitas-González E, Rivero-Lezcano OM

    Microorganisms 2024; (12(4)) doi:10.3390/microorganisms12040665.

    PMID: 38674609
  14. 14

    Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta™) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFBE): A clinical study protocol.

    Swenson CE, Hunt WR, Manfredi C, et al.

    PloS one 2025; (20(2)):e0316721 doi:10.1371/journal.pone.0316721.

    PMID: 39951444
  15. 15

    Clinical characteristics of pulmonary non-tuberculous mycobacterial disease with CFTR variants in the Japanese population.

    Nagao G, Namkoong H, Tanaka H, et al.

    BMJ open respiratory research 2026; (13(1)) doi:10.1136/bmjresp-2025-003683.

    PMID: 41638757

This page explains why clinicians may check for immune problems and underlying lung disease after pulmonary MAC, but it is for informational purposes only and does not constitute medical advice. Ask your clinician which tests are appropriate, and do not change prescribed medicines without guidance.

Get notified when new evidence is published on Mycobacterium avium complex disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.